Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 42

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

254

HTML

1224

Figures (1-1)

254

Tables (1-4)

227

Sum=1959

Nov 14, 2007 (publication date) through Dec 1, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Nov 14, 2007; 13(42): 5642-5647
Published online Nov 14, 2007. doi: 10.3748/wjg.v13.i42.5642

Table 2 Virological responses in the two treatment groups n (%)

	Lam-100 (n = 35)	Lam-200 (n = 12)
Primary responses	29 (82)	12 (100)
Breakthroughs	7 (24.6)	2 (16.6)
End of study responses (amplicor)	22 (62.8)	10 (83.3)
Stably undetectable HBV-DNA by RT-PCR	18 (51.4)^a	10 (83.3)^a

^aP = 0.051; 51.4% vs 83.3%.

Citation: Stornaiuolo G, Stanzione M, Brancaccio G, Cuomo G, Precone V, Di Biase S, Felaco FM, Piccinino F, Gaeta GB. Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B. World J Gastroenterol 2007; 13(42): 5642-5647
URL: https://www.wjgnet.com/1007-9327/full/v13/i42/5642.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i42.5642